2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-E70127
    Serratiopeptidase 37312-62-2
    Serratiopeptidase (Brasan; Dasen) is an orally active zinc-containing metalloprotease belonging to the serralysin family. Serratiopeptidase reduces the release of inflammatory mediators such as prostaglandins, thromboxanes and interleukins by inhibiting COX, thereby relieving pain, swelling and redness. Serratiopeptidase exhibits antibiofilm, mucolytic and wound-healing activities. As a serine protease, Serratiopeptidase has the ability to dissolve blood clots, fibrin and atherosclerotic plaques. Serratiopeptidase degrades amyloid fibrils and has potential anti-Alzheimer's effects. Serratiopeptidase shows cytotoxicity against colon cancer cells.
    Serratiopeptidase
  • HY-N0728A
    α-Linolenic acid sodium 822-18-4
    α-Linolenic acid sodium (ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3) is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid sodium can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid sodium possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer.
    α-Linolenic acid sodium
  • HY-P10887
    Pegevongitide 2988012-71-9 99.31%
    Pegevongitide is an agonist of the angiopoietin-1 receptor.
    Pegevongitide
  • HY-P1236A
    Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse TFA 99.32%
    Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
    Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse TFA
  • HY-P1515A
    Angiotensin II (3-8), human TFA 99.14%
    Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT1 receptor.
    Angiotensin II (3-8), human TFA
  • HY-P1519B
    Brain Natriuretic Peptide (1-32), rat acetate 98.66%
    Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).
    Brain Natriuretic Peptide (1-32), rat acetate
  • HY-P2281A
    Atrial natriuretic factor (1-28) (human, porcine) TFA 98.23%
    Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) TFA inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) TFA increases cGMP levels in RMIC cells with an IC50 of 1.2 nM.
    Atrial natriuretic factor (1-28) (human, porcine) TFA
  • HY-P3429A
    SAMβA TFA 99.13%
    SAMβA TFA is a rationally designed selective antagonist of Mfn1-βIIPKC association and can bind to TAT (HY-P0281). SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
    SAMβA TFA
  • HY-P5875A
    P4pal10 TFA 98.25%
    P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models.
    P4pal10 TFA
  • HY-P99891
    Rovelizumab 339086-79-2
    Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.
    Rovelizumab
  • HY-100672B
    (2R)-SR59230A 1932675-95-0 99.98%
    (2R)-SR59230A is the isomer of SR59230A (HY-100672), and can be used as an experimental control. SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
    (2R)-SR59230A
  • HY-103317A
    NAADP tetrasodium 99.1%
    NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases.
    NAADP tetrasodium
  • HY-105559A
    Viquidil hydrochloride 52211-63-9 99.93%
    Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity.
    Viquidil hydrochloride
  • HY-106592A
    U-74389G 153190-29-5 99.08%
    U-74389G (PNU74389G meleate) is an antioxidant, can inhibit lipid peroxidation reactions. U-74389G can protect against ischemia-reperfusion injury and be widely used in animal models of ischemic injury and hypertension. U-74389G shows anti-inflammatory activity.
    U-74389G
  • HY-111326A
    Naphazoline nitrate 5144-52-5 ≥98.0%
    Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research.
    Naphazoline nitrate
  • HY-114161A
    H-Val-Pro-Pro-OH TFA 2828433-08-3 ≥98.0%
    H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
    H-Val-Pro-Pro-OH TFA
  • HY-114164C
    Thrombin, Pig blood 9002-04-4
    Rabbit Thrombin is a Na+-activated, allosteric serine protease that plays opposing functional roles in blood coagulation. Thrombin recognition sequence and can be used to digest GST-tagged proteins.
    Thrombin, Pig blood
  • HY-114424A
    H-Ile-Pro-Pro-OH hydrochloride 1208862-61-6 99.66%
    H-Ile-Pro-Pro-OH hydrochloride, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.
    H-Ile-Pro-Pro-OH hydrochloride
  • HY-118824A
    N-Feruloylserotonin 68573-23-9 99.93%
    N-Feruloylserotonin ((E/Z)-Moschamine) is a serotonin hydroxycinnamic acid amide. It can be isolated from a variety of plants, particularly the seeds of safflower (Carthamus tinctorius L.). N-Feruloylserotonin inhibits KCl- and 5-HT-induced elevation of intracellular [Ca2+]i. It suppresses PDGF-BB-induced phosphorylation of PDGFRβ and ERK1/2. N-Feruloylserotonin exerts anti-inflammatory effects on aortic endothelial cells. It inhibits atherosclerotic plaque formation in apolipoprotein E-deficient mice.
    N-Feruloylserotonin
  • HY-125864B
    Murine Fibrinogen 9001-32-5
    Murine Fibrinogen is a native fibrinogen derived from mouse plasma. Murine Fibrinogen acts as a cerebrovascular permeability enhancer. Murine Fibrinogen activates matrix metalloproteinase-9 (MMP-9), downregulates the expression of vascular endothelial cadherin (VE-cadherin), and upregulates the expression of plasmalemmal vesicle-associated protein-1 (PV-1). Murine Fibrinogen increases macromolecular leakage from pial veins, thereby disrupting the microvascular integrity of cerebral blood vessels. Murine Fibrinogen can be used in studies related to cerebrovascular dysfunction.
    Murine Fibrinogen
Cat. No. Product Name / Synonyms Application Reactivity